Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Tumor mutational burden (TMB) has received significant attention within ongoing pursuits of
biomarkers of response to immune checkpoint inhibitors, and notably received FDA …

The immune-specialized environment of the healthy brain is tightly regulated to prevent
excessive neuroinflammation. However, after cancer development, a tissue-specific conflict …

Defects in pathways governing genomic fidelity have been linked to improved response to
immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause …

Immunotherapy as an alternative treatment strategy for B-cell lymphoma is undesirable
because of tumor heterogeneity and immune surveillance. Spermidine (SPM), as a regulator …

Highly coordinated changes in gene expression underlie T cell activation and exhaustion.
However, the mechanisms by which such programs are regulated and how these may be …

Since the past decades, more lung cancer patients have been experiencing lasting benefits
from immunotherapy. It is imperative to accurately and intelligently select appropriate …

Cancer development is an evolutionary process. A key selection pressure is exerted by
therapy, one of the few players in cancer evolution that can be controlled. As such, an …

The field of human space travel is in the midst of a dramatic revolution. Upcoming missions
are looking to push the boundaries of space travel, with plans to travel for longer distances …